Cet anticorps anti-IL-12, IL-23 (Ustekinumab Biosimilar) Monoclonal Souris (ABIN7795099) détecte spécifiquement IL-12, IL-23 (Ustekinumab Biosimilar) dans FACS et in vivo.
L’anticorps est réactif avec des échantillons de Humain.
Aperçu rapide pour Recombinant IL-12, IL-23 (Ustekinumab Biosimilar) anticorps (ABIN7795099)
Antigène
IL-12, IL-23 (Ustekinumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Souris
Clonalité
Monoclonal
Conjugué
Cet anticorp IL-12, IL-23 (Ustekinumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Expression System
Mammalian cells
Fonction
Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody
Attributs du produit
What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.